- Home
- HONE vs XERS Comparison
HONE vs XERS Comparison
Compare HONE & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HONE
- XERS
- Stock Information
- Founded
- HONE 1917
- XERS 2005
- Country
- HONE United States
- XERS United States
- Employees
- HONE N/A
- XERS N/A
- Industry
- HONE Major Banks
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- HONE Finance
- XERS Health Care
- Exchange
- HONE Nasdaq
- XERS Nasdaq
- Market Cap
- HONE 529.8M
- XERS 444.0M
- IPO Year
- HONE 2016
- XERS 2018
- Fundamental
- Price
- HONE $12.93
- XERS $3.35
- Analyst Decision
- HONE Hold
- XERS Strong Buy
- Analyst Count
- HONE 1
- XERS 3
- Target Price
- HONE $13.00
- XERS $4.67
- AVG Volume (30 Days)
- HONE 225.8K
- XERS 1.3M
- Earning Date
- HONE 10-24-2024
- XERS 11-08-2024
- Dividend Yield
- HONE 2.44%
- XERS N/A
- EPS Growth
- HONE N/A
- XERS N/A
- EPS
- HONE 0.27
- XERS N/A
- Revenue
- HONE $158,656,000.00
- XERS $181,413,000.00
- Revenue This Year
- HONE N/A
- XERS $20.35
- Revenue Next Year
- HONE $0.58
- XERS $16.14
- P/E Ratio
- HONE $49.08
- XERS N/A
- Revenue Growth
- HONE N/A
- XERS 35.31
- 52 Week Low
- HONE $9.16
- XERS $1.46
- 52 Week High
- HONE $14.00
- XERS $3.42
- Technical
- Relative Strength Index (RSI)
- HONE 54.32
- XERS 70.43
- Support Level
- HONE $11.41
- XERS $3.10
- Resistance Level
- HONE $13.61
- XERS $3.39
- Average True Range (ATR)
- HONE 0.62
- XERS 0.14
- MACD
- HONE 0.05
- XERS 0.01
- Stochastic Oscillator
- HONE 73.12
- XERS 83.72
About HONE HarborOne Bancorp Inc.
HarborOne Bancorp Inc is a bank holding company. The company is engaged in providing financial services like accepting deposits, lending loans, online and mobile banking, cash management, credit cards, money market accounts, and wealth management. The Company has two reportable segments: HarborOne Bank and HarborOne Mortgage. The bank provides financial services to individuals and businesses online and through its full-service branches located in Massachusetts and Rhode Island, one limited-service branch, and a commercial lending office in each of Boston, Massachusetts and Providence, Rhode Island.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.